NRX Pharmaceuticals' Price Target Boosted to $34 by D. Boral Capital Analyst.

NRX Pharmaceuticals' stock evaluation has been boosted by D. Boral Capital, which raised the price target to $34.00 USD, a 9.68% increase, and maintained a "Buy" rating. This indicates a strong positive sentiment towards the stock's future performance. The average target price for NRX Pharmaceuticals is $29.25, implying a 1,056.13% upside from the current price. The average brokerage recommendation is 1.8, indicating an "Outperform" status.

NRX Pharmaceuticals' stock evaluation has been significantly boosted by D. Boral Capital, which raised the price target to $34.00 USD, a 9.68% increase, and maintained a "Buy" rating. This indicates a strong positive sentiment towards the stock's future performance. The average target price for NRX Pharmaceuticals is $29.25, implying a 1,056.13% upside from the current price. The average brokerage recommendation is 1.8, indicating an "Outperform" status.

D. Boral Capital's positive outlook on NRX Pharmaceuticals is supported by the company's innovative pipeline and recent regulatory milestones. NRX Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company has received significant regulatory approvals, including the FDA's Fast Track Designation for NRX-100, a promising treatment for suicidal ideation in depression [1].

Despite facing financial challenges, NRX Pharmaceuticals reported a net loss of $14.425 million in Q2 2025, driven by high operating expenses and R&D costs. The company's EPS estimate remains positive at $0.07, reflecting analysts' optimism about the company's long-term prospects [2]. The next catalyst for investors will be the company's guidance for the remainder of 2025, which could signal whether management has a viable strategy for reducing expenses or accelerating product development.

Investors should be mindful of the company's financial challenges and the pharmaceutical sector's regulatory uncertainty and rising R&D costs. While NRX Pharmaceuticals presents significant investment opportunities, it is essential to weigh the risks associated with its current financial performance and operational challenges.

References
[1] https://www.ainvest.com/news/nrx-pharmaceuticals-maintains-buy-rating-31-price-target-2508/
[2] https://www.ainvest.com/news/nrx-pharmaceuticals-q2-2025-earnings-market-impact-strategic-insights-2508/